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Background: Serum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be
associated with clinical outcomes. A disintegrin and metalloproteinase-10, a sheddase of HER2/neu, can drive
cancer progression and its activity is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1). However, elevated
TIMP-1 expression has been associated with a poor prognosis of breast cancer. Therefore, this study was performed
to explore the relationships between serum HER2 ECD, TIMP-1 and clinical outcomes.
Methods: One hundred and eighty-five female breast cancer patients, who received curative mastectomy without
neo-adjuvant chemotherapy at Chang-Gung Memorial Hospital, were recruited with informed consent for this study.
Pre-operative serum levels of HER2 ECD and TIMP-1 were measured using an enzyme-linked immunosorbent assay.
Results: Twenty-three cases (12.4%) were classified HER2 ECD positive. HER2 ECD positivity was significantly associated
with age, lymph node involvement, histological grade, estrogen receptor status, progesterone receptor status, tissue
HER2/neu overexpression, and disease-free survival (DFS). In an age, stage, ER and HER2/neu status matched subgroup
(N = 41), the serum level of TIMP-1 was significantly associated with HER2 ECD positivity and DFS.
Conclusions: A high serum TIMP-1 was significantly associated with HER2 ECD positivity and a poorer DFS among
Taiwanese primary breast cancer patients with HER2 overexpression.
Keywords: breast cancer, HER2 ECD, TIMP-1, enzyme-linked immunosorbent assay, prognosis
Background
Amplification or overexpression of HER2/neu, a 185
kDa transmembrane tyrosine kinase receptor, has been
reported in 20-30% of invasive breast cancers (IBCs) [1].
It predicts a more aggressive clinical course such as a
transition from in situ growth to invasion [2], aggressive
disease progression and poor treatment response [3-5].
In addition, it has been shown that there is a high con-
cordant HER2/neu status in paired primary tumor and
distant metastatic lesions on analysis by both immuno-
histochemistry (IHC) and by fluorescence in situ hybri-
dization (FISH) [6-9]. Therefore, HER2/neu status is an
important diagnostic and prognostic biomarker and is
also one of the most dependable criteria for the use of
trastuzumab-based chemotherapy to treat breast cancer.
In addition to HER2/neu status of the tumor tissue, the
extracellular domain (ECD) of HER2 (HER2 ECD), which
is shed from the HER2/neu receptor after a proteolysis
process, has been shown to show a better correlation
with tumor burden, treatment response, disease-free sta-
tus and overall survival than the full-length HER2/neu
[10]. However, certain clinical studies have not supported
baseline serum HER2 ECD as a reliable predictor of
tumor progression, treatment response, duration of
response, or time to progression in advanced/metastatic
breast cancer [11,12]. Thus, in agreement with the 2007
and 2009 American Society of Clinical Oncology guide-
lines on the use of biomarkers in breast cancer [11,13],
there is currently insufficient evidence to support the use
of serum HER-2 ECD in the routine management of indi-
vidual patients with breast cancer.
It has been demonstrated that extracellular matrix
remodeling proteinases, such as matrix metalloprotei-
n a s e s( M M P s ) ,p l a yak e yr o l ei nt h ei n v a s i o na n d
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indicated that members of a zinc-dependent family of
proteinases related to the MMPs, namely disintegrin
and metalloproteinases (ADAMs), are also involved in
cancer progression [17]. A major level of control MMP
functions occurs via their interaction with specific tissue
inhibitors of metalloproteinases (TIMPs) [18]. Similar to
MMPs, ADAM family members are also inhibited by
specific TIMPs [17]. Among known MMPs and
ADAMs, ADAM-10 has been shown to play an impor-
tant role in the shedding of dozens of substrates that
drive cancer progression, including HER2/neu [19,20].
Furthermore, HER2 ECD shedding can be inhibited by
broad-spectrum metalloprotease inhibitors such as
TAPI, batimastat, and TIMP-1[ 1 9 , 2 1 ] .H o w e v e r ,e l e -
vated TIMP-1 expression in human cancers, including
breast cancer, has been associated with a decreased time
to recurrence and a lower overall survival [22-26].
It is well known that there are significant ethnic dispa-
rities between western and eastern countries in terms of
breast cancer with respect to cancer incidence, the fre-
quency of BRCA1 and BRCA2 mutation, tumor biology
and molecular subtypes [27-29]. In this context, infor-
mation on the role of serum HER2 ECD in Asian breast
cancer women is limited. Therefore, this study was per-
formed to explore the relationships between serum
HER2 ECD level, serum TIMP-1 level and clinical out-
comes. Since MMP-2 and MMP-9 (gelatinase A and B)
have been shown to be associated with breast cancer,
expression of HER2/neu, and an unfavorable prognosis
[15,16] and because TIMP-2 also seems to have cell
growth promoting and anti-apoptotic activity [30],
serum MMP-2, MMP-9 and TIMP-2 were also included
in the present analysis.
Methods
Patients and Clinicopathological Information Collection
This study was approved by the Institutional Review
Board, Chang Gung Memorial Hospital (CGMH). One
hundred and eighty-five female breast cancer patients
received curative mastectomy without neo-adjuvant che-
motherapy during 2001 and 2002 in CGMH and were
retrospectively recruited with informed consent from
our clinical sample library for this study. In order to
have reasonable case numbers for studying the relation-
ships between serum HER2 ECD and TIMP-1, the pre-
sent cohort was intentionally comprised of most cases
with HER2 overexpression. In addition, 23 women who
came to CGMH for health examination during the same
period and who were without cancer or other critical
chronic disease, were also recruited with informed con-
sent as normal controls. Clinicopathological information
on the 185 breast cancer patients, including age, meno-
pause status, echo-determined tumor size, lymph node
metastasis, stage, DNA ploidy, SBR tumor grade, estro-
gen receptor status (ER), progesterone receptor status
(PR), and HER2/neu evaluated by immunohistochemis-
try, regimens of treatment, disease-free and overall sur-
vival time, were collected.
Analysis of Serum HER2 ECD, MMP-2, MMP-9, TIMP-1 and
TIMP-2
Serum was collected from the control individuals during
their physical examination and from the breast cancer
patients before surgery; the samples were then stored at
-70°C until they were assayed. The level of serum HER2
ECD was determined by enzyme-linked immunosorbent
assay (ELISA) at Department of Clinical Pathology,
CGMH, using two monoclonal antibodies that recog-
nized a distinct epitope of the ECD of the HER2 protein
as described previously [31]. All samples were assayed in
duplicate. Since the mean value of the serum HER2
ECD of the 23 normal controls was 8.9 ng/ml, we
defined individuals with a HER2 ECD level higher than
8.9 ng/ml as HER2 ECD-positive.
Serum levels of MMP-2, MMP-9, TIMP-1 and TIMP-
2 were measured using a Biotrak ELISA System (Amer-
sham Pharmacia Biotech Inc., USA). All samples were
assayed in duplicate. According to the manufacture’s
protocol, 100 μl of diluted serum samples were added to
the assay and the levels of MMP-2, MMP-9, TIMP-1
and TIMP-2 were determined using appropriate peroxi-
dase-conjugated anti- MMP-2, MMP-9, TIMP-1 and
TIMP-2 antibodies. The reactions were stopped by the
addition of 100 μl of 1 M sulfuric acid and absorbance
of the product was read at 450 nm within 30 minutes.
Statistical Analysis
Statistical analysis was performed using SPSS version
11.0 (SPSS, Chicago, IL). The associations between the
clinicopathological parameters and the HER2 ECD sta-
tus were examined using the c
2-squared test or Fisher’s
exact test. Wilcoxon Rank Sums test and Fisher’s exact
test were used to compare all clinicopathological cate-
gories between the HER2 ECD positive and negative
patients. Serum protease levels in the matched groups
were also analyzed by the same methods. Survival curves
were constructed using the Kaplan-Meier method and
compared with the log-rank test (univariate analysis).
Multivariate analysis was carried out using the Cox risk
proportion model. A two-sided value of p <0 . 0 5w a s
considered statistically significant.
Results
Relationship between Baseline Serum HER2 ECD Levels
and Clinicopathological variables
Pre-operative serum and complete clinicopathological
information were retrospectively collected from 185
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and 2002. Using the cut-off serum HER2 ECD level of
8.9 ng/ml, which is the mean value for the 23 normal-
control females, 23 (12.4%) patients had serum HER2
ECD levels designated as positive. As shown in Table 1
HER2 ECD positivity was significantly associated with
being older (p = 0.002), having lymph node involvement
(p = 0.010), having an advanced stage (p < 0.0001), hav-
ing a high histological grade (p = 0.029), the presence of
non-diploid tumor DNA (p = 0.033), having a negative
ER (p = 0.0002), having a negative PR (p = 0.015) and
HER2/neu overexpression (p = 0.003).
Disease-free survival and overall survival (DFS and
OS) were significantly worse in patients that were serum
HER2 ECD positive at diagnosis when compared with
patients that were HER2 ECD negative (Figure 1). To
assess the effect of the other clinicopathological vari-
ables and treatment on DFS and OS, a Cox model was
carried out initially using univariate analysis. Being older
(p = 0.037), lymph node involvement (p = 0.003), nega-
tive ER status (p = 0.0008) and non-hormone therapy (p
= 0.001) were significantly associated with a poorer DFS
(Table 2). Lymph node involvement (p =0 . 0 0 2 ) ,n e g a -
tive ER status (p = 0.002) and non-hormone therapy (p
= 0.001) were significantly associated with a poorer OS
(Table 2). A multivariate Cox regression model for DFS
and OS was then built using the variables that were
found to be significant during the univariate analysis
and lymph node involvement and negative ER status
were significantly associated with poorer DFS and OS.
In addition, hormone therapy would seem to improve
DFS and OS (Table 2).
Relationship between Serum levels of MMPs, TIMPs and
HER2 ECD
To determine the type of protease associated with
higher serum HER2 ECD levels, the serum levels of two
metalloproteases (MMP-2 and MMP-9) and two pro-
tease inhibitors (TIMP-1 and TIMP-2) were analyzed
within a matched design. Age, stage, ER and HER2/neu
status were used for matching to rule out their effects
on HER2 ECD positivity (Table 1). In the end nineteen
HER2 ECD positive samples and twenty-two HER2 ECD
negative samples were enough for this analysis. As
shown in Table 3 the serum level of TIMP-1 was signifi-
cantly higher in HER2 ECD positive patients compared
to HER2 ECD negative patients. However, there were no
significant differences between HER2 ECD positive and
negative patients in terms of their serum MMP-2,
MMP-9, and TIMP-2 levels.
Combined Effect of Serum TIMP-1 and HER2 ECD Levels
on Clinical Outcomes
Since it has been reported that serum TIMP-1 was an
independent predictive and prognostic factor for meta-
static breast cancer [32], the effect of serum TIMP-1
and the combined effect of serum TIMP-1 and HER2
ECD on clinical outcomes was also explored using age,
stage, ER and HER2/neu status matched patients (a total
of 41 patients). The breast cancer patients were dichoto-
mized into high and low TIMP-1 groups based on a
median value of 270 ng/mL. Patients with a low TIMP-
1 level and who were ECD negative were defined as the
low-risk group, while the others were defined as the
high-risk group. As shown in Figure 2, low serum
TIMP-1 patients had significantly better DFS than high
Table 1 The associations between serum ECD level and










< = 50 91 (94.8%) 5 (5.2%) 0.002*
> 50 71 (79.8%) 18 (20.2%)
Tumor size (cm)
< = 3 114 (90.5%) 12 (9.5%) 0.080
> 3 48 (81.4%) 11 (18.6%)
Lymph node status
Negative 102 (92.7%) 8 (7.3%) 0.010*
Positive 60 (80.0%) 15 (20.0%)
Stage
0 13 (92.9%) 1 (7.1%) <
0.0001*
I 37 (97.4%) 1 (2.6%)
II 95 (90.5%) 10 (9.5%)
III 17 (60.7%) 11 (39.3%)
SBR grade
Low 81 (92.0%) 7 (8.0%) 0.029*
High 52 (80.0%) 13 (20.0%)
DNA ploidy
Diploid 40 (95.2%) 2 (4.8%) 0.033*
a
Non-diploid 69 (80.2%) 17 (19.8%)
Estrogen receptor status (ER)
Negative 93 (80.9%) 22 (19.1%) 0.0002*
a
Positive
† 69 (98.6%) 1 (1.4%)
Progesterone receptor status
(PR)
Negative 107 (83.6%) 21 (16.4%) 0.015*
a
Positive 55 (96.5%) 2 (3.5%)
HER2/neu expression (IHC)
Negative or Weak 43 (100.0%) 0 (0.0%) 0.003*
a
Strong (> = 3+) 119 (83.8%) 23 (16.2%)
*statistically significant at p < 0.05.
†Monoclonal antibody 6F11 was used as the primary antibody for ER IHC
staining and the cutoff was set at 10% of tumor cells displayed staining to
define “ER positive”.
aby Fisher’s exact test
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of serum TIMP-1 on OS was insignificant (p = 0.215).
Furthermore, the effects of serum TIMP-1 on clinical
outcomes were strengthened when the serum HER2
ECD was taken into account.
Discussion
The clinical roles of serum HER2 ECD in breast cancer
have been widely discussed since this protein was first
discovered. The percentage of serum HER2 ECD posi-
tivity has been found to be extremely variable in primary
breast cancer patients. In our study, HER2 ECD positiv-
ity was detected in 12.4% (23/185). This rate is close to
t h em e a nv a l u eo ft h ew o r l d w i d es t u d i e sp u b l i s h e d
between 1992 and 2007 [12], although the cut-off value
in our study (8.9 ng/mL) is different from the value (15
ng/mL) cleared by the US Food and Drug
Administration for use in the management of women
with metastatic breast cancer [33].
High serum concentrations of HER2 ECD have been
associated with HER2 overexpression [34], increased
tumor burden [35], poorer survival [36] and resistance
to endocrine therapy and chemotherapy [12,37,38], We
f o u n dt h a tH E R 2E C Dp o s i t i v i ty was significantly asso-
ciated with most clinicopathological parameters includ-
ing tumor size, lymph node involvement, tumor stage,
histological grade, chromosome ploidy, ER, PR, and
HER2/neu membrane protein overexpression. These
results imply that serum HER2 ECD levels may reflect
the aggressiveness of the disease better than tissue
HER2/neu receptor only. It is interesting to note that
older patients had higher HER2 ECD positivity than
younger patients in this series of patients. This phenom-
enon can be explained by the differences in the
Figure 1 Kaplan-Meier curves for disease-free survival and overall survival based on the analysis of serum HER2 ECD positivity.
Table 2 Univariate and multivariate analysis of disease free survival and overall survival
Variables Disease-free survival Overall survival
p value p value
Univariate Multivariate HR
a (95% CI) Univariate Multivariate HR
a (95% CI)
Age 0.037 0.205
b 1.53 (0.79 - 2.96)
b 0.138
0.278
c 1.44 (0.75 - 2.78)
c
Tumor size 0.862 0.563
Lymph node 0.003 0.003
b 2.70 (1.40 - 5.23)
b 0.002 0.002
b 2.81 (1.46 - 5.42)
b
0.008
c 2.41 (1.25 - 4.64)
c 0.005
c 2.57 (1.34 - 4.93)
c
ER 0.0008 0.004
b 3.79 (1.53 - 9.38)
b 0.002 0.004






b 1.62 (0.76 - 3.47)
b 0.005 0.451
b 1.34 (0.62 - 2.90)
b
0.097
c 1.89 (0.89 - 3.99)
c 0.341
c 1.45 (0.68 - 3.09)
c
Chemotherapy* 0.122 0.224
Radiation therapy 0.418 0.859
Hormone therapy 0.001 0.011
c 0.31 (0.13 - 0.77)
c 0.001 0.004
c 0.27 (0.11 - 0.65)
c
* Anthracycline-based regimen (82/185, 44.3%), CMF (cyclophosphamide, methotrexate and 5-fluorouracil) (64/185, 34.6%), taxane (45/185, 24.3%), trastuzumab
(22/185, 11.9%), lapatinib (3/185, 1.6%) and others (28/185, 15.1%) were used as the first line adjuvant chemotherapy in this breast cancer cohort.
aAdjusted for other prognostic variables as listed on the left.
b, cSince most patients who were ER positive underwent hormone therapy, ER and hormone therapy were included in the model separately.
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groups of patients. In the present study, the frequencies
of ER and PR negativity were significantly higher in
older patients (70.8% and 83.2% for ER and PR, respec-
tively) than younger patients (54.2% and 56.3% for ER
and PR, respectively). The data from Taiwan Cancer
Database also consistently shows that younger patients
(≤50 years) have a higher prevalence of ER and PR
expression compared with older patients (> 50 years)
[27].
Table 3 Differences in serum MMP-2, MMP-9, TIMP-1 and








MMP-2 685.09 ± 148.30 753.14 ± 219.17 0.359
MMP-9 39.85 ±29.97 40.82 ± 33.66 0.979
TIMP-1 242.45 ± 102.82 364.88 ± 139.38 0.006
TIMP-2 49.23 ± 21.81 62.92 ± 42.11 0.528
aby Wilcoxon two-sample test.
Figure 2 Kaplan-Meier curves for disease-free survival and overall survival based on the analysis of serum TIMP-1 level (A, B), HER2
ECD positivity (C, D) and their combination (E, F) in 41 age, stage, ER and HER2/neu status matched patients.
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as an independent prognostic marker in one study by
Ludovini et al. [39]. In the present study, serum HER2
ECD positivity was also associated with shorter DFS and
OS in the univariate analysis. Probably due to a small
number of positive HER2 ECD cases (n = 23), these
associations were not significant in the multivariate ana-
lysis (Table 2). However, serum HER2 ECD positivity
was a better predictor than HER2/neu status by IHC as
indicated by previous studies [10,39].
The mechanism of HER2 ECD shedding from HER2/
neu receptor is not been completely understood. It had
been demonstrated that HER2 is one of the shedding
substrates of ADAM-10 [19] and HER2 ECD shedding
can be enhanced by fatty acid synthase [40] and inhib-
ited by the broad-spectrum metalloprotease inhibitors
such as TAPI, batimastat, and TIMP-1 [21]. In this
study, we found that serum levels of TIMP-1 were sig-
nificantly higher in HER2 ECD positive patients com-
pared to HER2 ECD negative patients after correction
for various clinicopathological factors (age, stage, ER
and HER2/neu status). This observation was unexpected
and contrary to the findings of the in vitro model sys-
tem [21,41]. TIMP-1 is the prototypic inhibitor for most
MMP family members [42]. Recent studies, however,
have indicated that TIMP-1 also possesses a broad
range of MMP independent biological activities includ-
ing the induction of proliferation and the inhibition of
apoptosis [43]. The induction of proliferation and the
inhibition of apoptosis by TIMP-1 have been demon-
strated to occur through activation of the phosphatidyl
inositol-3 kinase (PI-3K) signaling pathway [44-46].
Furthermore, activation of PI-3K can lead to activation
of phosphatidyl inositol-dependent kinase-1 (PDK1),
which directly phosphorylates ADAMs and causes EGFR
activation [47]. Therefore, it is possible that in some cir-
cumstances a high level of TIMP-1 may activate
ADAM-10, which would directly lead to HER2 ECD
shedding. The double-edged sword of TIMP-1 in terms
of activation and inhibition of ADAM-10 activity and
the effect of this on HER2 ECD shedding needs further
investigation.
Since Talvensaari-Mattila et al. [26] reported that high
serum TIMP-1 levels are significantly correlated with
poorer relapse-free survival among breast cancer patients,
several studies have obtained similar findings [48]. In our
small matched study subjects (N = 41), adjuvant treatment
was not different for the different TIMP-1 and HER2 ECD
g r o u p s .W eo b s e r v e dt h a th i g hs e r u ml e v e l so fT I M P - 1
were associated with a poorer DFS, but not HER2 ECD
(Figure 2). Furthermore, patients with a low TIMP-1 and a
negative HER2 ECD had better clinical outcomes than the
other combinations (Figure 2). This observation is similar
to a study by Lipton et al. [49] They found that a
combined analysis of both serum TIMP-1 and HER2/neu
conferred an additional ability to predict subgroups of
patients with significantly different clinical outcomes as
compared to using either biomarker alone.
Conclusions
A high serum TIMP-1 was significantly associated with
HER2 ECD positivity and a poorer DFS among Taiwa-
nese primary breast cancer patients with HER2 overex-
pression. Combined analysis of both serum TIMP-1 and
HER2 ECD may have additional value when used for
the clinical management of breast cancer patients with
HER2 overexpression in Taiwan.
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